Scarica l'app Stockscreener
1.82
0.55%
-0.01
Proqr Therapeutics N V Borsa (PRQR) Ultime notizie
ProQR Therapeutics' SWOT analysis: RNA editing firm's stock faces pivotal phase - Investing.com India
ProQR Therapeutics' SWOT analysis: RNA editing firm's stock faces pivotal phase - Investing.com UK
ProQR Therapeutics (NASDAQ:PRQR) Shares Pass Below Two Hundred Day Moving Average of $1.95 - MarketBeat
ProQR Therapeutics N.V (PRQR) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Market Momentum: ProQR Therapeutics N.V (PRQR) Registers a 7.14 Increase, Closing at 1.80 - The Dwinnex
ProQR Therapeutics (NASDAQ:PRQR) Shares Cross Below Two Hundred Day Moving Average of $1.96 - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Stock Passes Below Two Hundred Day Moving Average of $1.96 - Defense World
ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference - GlobeNewswire
ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference - StockTitan
ProQR Therapeutics (NASDAQ:PRQR) Share Price Passes Above 50-Day Moving Average of $1.90 - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Stock Price Crosses Above 50-Day Moving Average of $1.90 - Defense World
A look into ProQR Therapeutics N.V (PRQR)’s deeper side - SETE News
What technical indicators reveal about PRQR stock - US Post News
ProQR Announces Presentation on its Axiomer™ RNA Editing Technology at RNA Editing Summit - Yahoo Finance UK
ProQR Therapeutics NV (FRA:0PQ) Financial Strength : 3 (As of Jun. 2024) - GuruFocus.com
Reviewing ProQR Therapeutics (NASDAQ:PRQR) and OptiNose (NASDAQ:OPTN) - Defense World
ProQR Therapeutics NV (FRA:0PQ) Enterprise Value : €86.81 Mil (As of Aug. 17, 2024) - GuruFocus.com
Comparing Moleculin Biotech (NASDAQ:MBRX) & ProQR Therapeutics (NASDAQ:PRQR) - Defense World
ProQR: Q2 Earnings Snapshot - San Antonio Express-News
ProQR: Q2 Earnings Snapshot - San Francisco Chronicle
ProQR Therapeutics N.V. Financial Performance Review - TipRanks
ProQR Announces Second Quarter 2024 Operating and Financial Results - GlobeNewswire
ProQR Announces Second Quarter 2024 Operating and Financial Results - Yahoo Finance
Virtu Financial LLC Has $59,000 Position in ProQR Therapeutics (NASDAQ:PRQR) - Defense World
Acadian Asset Management LLC Takes $56,000 Position in ProQR Therapeutics (NASDAQ:PRQR) - Defense World
BNP Paribas Financial Markets Increases Position in ProQR Therapeutics (NASDAQ:PRQR) - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Share Price Passes Below Two Hundred Day Moving Average of $2.00 - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Share Price Crosses Below Two Hundred Day Moving Average of $2.00 - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Shares Pass Below Two Hundred Day Moving Average of $2.01 - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Stock Passes Below Two Hundred Day Moving Average of $2.01 - MarketBeat
ProQR Therapeutics N.V. (NASDAQ:PRQR) Investors Are Less Pessimistic Than Expected - Simply Wall St
StockNews.com Upgrades ProQR Therapeutics (NASDAQ:PRQR) to Hold - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Sees Significant Drop in Short Interest - MarketBeat
StockNews.com Upgrades ProQR Therapeutics (NASDAQ:PRQR) to “Hold” - Defense World
Individual investors account for 45% of ProQR Therapeutics N.V.'s (NASDAQ:PRQR) ownership, while institutions ... - Yahoo New Zealand News
ProQR (PRQR) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Movies UK
RFG Advisory LLC Makes New $73,000 Investment in ProQR Therapeutics (NASDAQ:PRQR) - Defense World
ProQR (PRQR) Rises on Expanding RNA-Editing Deal With Eli Lilly - Yahoo Canada Shine On
ProQR Announces Upcoming Investor Conferences in November and December - Quantisnow
Lilly and ProQR to Expand RNA Editing Collaboration - Quantisnow
Regenxbio (RGNX) Soars 6.4%: Is Further Upside Left in the Stock? - Zacks Investment Research
Institutions own 25% of ProQR Therapeutics N.V. (NASDAQ:PRQR) shares but retail investors control 46% of the ... - Yahoo Finance UK
Institutions own 25% of ProQR Therapeutics N.V. (NASDAQ:PRQR) shares but retail investors control 46% of the company - Yahoo Finance
ProQR Therapeutics (NASDAQ:PRQR) Lowered to Sell at StockNews.com - Defense World
StockNews.com Lowers ProQR Therapeutics (NASDAQ:PRQR) to Sell - MarketBeat
ProQR (PRQR) Reports Q3 Loss, Tops Revenue Estimates - Yahoo New Zealand News
A stock that deserves closer examination: ProQR Therapeutics N.V (PRQR) – US Post News - US Post News
ProQR Announces Presentation on its Axiomer™ RNA Editing Technology at RNA Editing Summit - Markets Insider
ProQR Announces Presentation on its Axiomer™ RNA Editing Technology at RNA Editing Summit - EIN News
PRQRProQR Therapeutics N.V. Ordinary Shares Latest Stock News & Market Updates - StockTitan
Xilio Therapeutics Appoints Aoife Brennan and James Shannon to its Board of Directors - citybiz
Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D., to its Board of Directors - ForexTV.com
ProQR Therapeutics (NASDAQ:PRQR) Upgraded to "Hold" by StockNews.com - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Raised to “Hold” at StockNews.com - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Shares Pass Above 50 Day Moving Average of $2.02 - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Lowered to “Sell” at StockNews.com - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Shares Cross Above 50 Day Moving Average of $2.02 - MarketBeat
Will ProQR Therapeutics Continue to Surge Higher? - Yahoo Sport Australia
Broker Revenue Forecasts For ProQR Therapeutics N.V. (NASDAQ:PRQR) Are Surging Higher - Simply Wall St
Recent Investment Analysts' Ratings Updates for ProQR Therapeutics (PRQR) - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Shares Pass Below 50-Day Moving Average of $2.09 - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Shares Pass Below 50-Day Moving Average of $2.09 - Defense World
G1 Therapeutics stock slips on breast cancer data (NASDAQ:GTHX) - Seeking Alpha
Will ProQR (PRQR) Report Negative Q1 Earnings? What You Should Know - Yahoo Canada Shine On
0.05%
4.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):